ID

15192

Descrizione

Genomic Response Analysis of Heart Failure Therapy in African Americans; ODM derived from: https://clinicaltrials.gov/show/NCT02305095

collegamento

https://clinicaltrials.gov/show/NCT02305095

Keywords

versioni (1)
  1. 22/05/16 22/05/16 -
Caricato su

22 maggio 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Heart Failure NCT02305095

Inglese

Eligibility Heart Failure NCT02305095

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
18 years and older
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
history of heart failure with an lvef (less than or equal to) < 0.35 for at least 6 months or an lvef < 0.45 with left ventricular internal end diastole (defined by a diameter of more than 2.9 cm per square meter of body surface area or more than 6.5 cm on the basis of echocardiography).
Descrizione

Heart failure | Left ventricular ejection fraction | Diastolic left ventricular internal diameter End diastole | Body Surface Area | Echocardiography

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0018801
UMLS CUI [2]
C0428772
UMLS CUI [3,1]
C0919652
UMLS CUI [3,2]
C1562146
UMLS CUI [4]
C0005902
UMLS CUI [5]
C0013516
new york heart association (nyha) class ii-iv
Descrizione

New York Heart Association Classification

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1275491
background heart failure therapy that includes angiotensin converting enzyme inhibitors (acei) or angiotensin receptor blockers (arbs), and beta blockers (bbs) for at least 3 months (or documentation of intolerance to acei/arbs and bbs)
Descrizione

Therapeutic procedure Background Heart failure | Angiotensin-Converting Enzyme Inhibitors | Angiotensin II receptor antagonist | Adrenergic beta-Antagonists | intolerance to Angiotensin-Converting Enzyme Inhibitors | intolerance to Angiotensin II receptor antagonist | intolerance to Adrenergic beta-Antagonists ,

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1706907
UMLS CUI [1,3]
C0018801
UMLS CUI [2]
C0003015
UMLS CUI [3]
C0521942
UMLS CUI [4]
C0001645
UMLS CUI [5,1]
C1744706
UMLS CUI [5,2]
C0003015
UMLS CUI [6,1]
C1744706
UMLS CUI [6,2]
C0521942
UMLS CUI [7,1]
C1744706
UMLS CUI [7,2]
C0001645
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
no history of intolerance to either nitrates or hydralazine
Descrizione

intolerance to Nitrates | intolerance to Hydralazine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C0028125
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C0020223
no treatment with the combination of hydralazine and nitrates for the previous 3 months
Descrizione

Combination Drug Therapy Hydralazine Nitrates

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013218
UMLS CUI [1,2]
C0020223
UMLS CUI [1,3]
C0028125
no revascularization or myocardial infarction within last 90 days
Descrizione

Revascularization | Myocardial Infarction

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0581603
UMLS CUI [2]
C0027051
can not be enrolled for at least 90 days after receiving cardiac resynchronization therapy (crt) and must have an lvef (less than or equal to) < 0.35 at least 3 months after crt.
Descrizione

Cardiac Resynchronization Therapy | Left ventricular ejection fraction

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1167956
UMLS CUI [2]
C0428772
presence of clinically significant valvular heart disease, hypertrophic or restrictive cardiomyopathy, active myocarditis, or uncontrolled hypertension.
Descrizione

Heart valve disease | Hypertrophic Cardiomyopathy | Restrictive cardiomyopathy | myocarditis; active | Uncontrolled hypertension

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0018824
UMLS CUI [2]
C0007194
UMLS CUI [3]
C0007196
UMLS CUI [4]
C0238294
UMLS CUI [5]
C1868885
women who are currently pregnant, planning on becoming pregnant in the next two years, or those who do not agree to prevent pregnancy.
Descrizione

Pregnancy | Pregnancy, Planned | Pregnancy Preventing Unwilling

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0032992
UMLS CUI [3,1]
C0032961
UMLS CUI [3,2]
C1292733
UMLS CUI [3,3]
C0558080
Ritorna all'inizio della pagina

Similar models

Eligibility Heart Failure NCT02305095

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
18 years and older
boolean
C0001779 (UMLS CUI [1])
Heart failure | Left ventricular ejection fraction | Diastolic left ventricular internal diameter End diastole | Body Surface Area | Echocardiography
Item
history of heart failure with an lvef (less than or equal to) < 0.35 for at least 6 months or an lvef < 0.45 with left ventricular internal end diastole (defined by a diameter of more than 2.9 cm per square meter of body surface area or more than 6.5 cm on the basis of echocardiography).
boolean
C0018801 (UMLS CUI [1])
C0428772 (UMLS CUI [2])
C0919652 (UMLS CUI [3,1])
C1562146 (UMLS CUI [3,2])
C0005902 (UMLS CUI [4])
C0013516 (UMLS CUI [5])
New York Heart Association Classification
Item
new york heart association (nyha) class ii-iv
boolean
C1275491 (UMLS CUI [1])
Therapeutic procedure Background Heart failure | Angiotensin-Converting Enzyme Inhibitors | Angiotensin II receptor antagonist | Adrenergic beta-Antagonists | intolerance to Angiotensin-Converting Enzyme Inhibitors | intolerance to Angiotensin II receptor antagonist | intolerance to Adrenergic beta-Antagonists ,
Item
background heart failure therapy that includes angiotensin converting enzyme inhibitors (acei) or angiotensin receptor blockers (arbs), and beta blockers (bbs) for at least 3 months (or documentation of intolerance to acei/arbs and bbs)
boolean
C0087111 (UMLS CUI [1,1])
C1706907 (UMLS CUI [1,2])
C0018801 (UMLS CUI [1,3])
C0003015 (UMLS CUI [2])
C0521942 (UMLS CUI [3])
C0001645 (UMLS CUI [4])
C1744706 (UMLS CUI [5,1])
C0003015 (UMLS CUI [5,2])
C1744706 (UMLS CUI [6,1])
C0521942 (UMLS CUI [6,2])
C1744706 (UMLS CUI [7,1])
C0001645 (UMLS CUI [7,2])
Item Group
C0680251 (UMLS CUI)
intolerance to Nitrates | intolerance to Hydralazine
Item
no history of intolerance to either nitrates or hydralazine
boolean
C1744706 (UMLS CUI [1,1])
C0028125 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C0020223 (UMLS CUI [2,2])
Combination Drug Therapy Hydralazine Nitrates
Item
no treatment with the combination of hydralazine and nitrates for the previous 3 months
boolean
C0013218 (UMLS CUI [1,1])
C0020223 (UMLS CUI [1,2])
C0028125 (UMLS CUI [1,3])
Revascularization | Myocardial Infarction
Item
no revascularization or myocardial infarction within last 90 days
boolean
C0581603 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
Cardiac Resynchronization Therapy | Left ventricular ejection fraction
Item
can not be enrolled for at least 90 days after receiving cardiac resynchronization therapy (crt) and must have an lvef (less than or equal to) < 0.35 at least 3 months after crt.
boolean
C1167956 (UMLS CUI [1])
C0428772 (UMLS CUI [2])
Heart valve disease | Hypertrophic Cardiomyopathy | Restrictive cardiomyopathy | myocarditis; active | Uncontrolled hypertension
Item
presence of clinically significant valvular heart disease, hypertrophic or restrictive cardiomyopathy, active myocarditis, or uncontrolled hypertension.
boolean
C0018824 (UMLS CUI [1])
C0007194 (UMLS CUI [2])
C0007196 (UMLS CUI [3])
C0238294 (UMLS CUI [4])
C1868885 (UMLS CUI [5])
Pregnancy | Pregnancy, Planned | Pregnancy Preventing Unwilling
Item
women who are currently pregnant, planning on becoming pregnant in the next two years, or those who do not agree to prevent pregnancy.
boolean
C0032961 (UMLS CUI [1])
C0032992 (UMLS CUI [2])
C0032961 (UMLS CUI [3,1])
C1292733 (UMLS CUI [3,2])
C0558080 (UMLS CUI [3,3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial